

Table. Current state of development and validation of biomarkers for the early and differential diagnosis of Alzheimer's disease. Phases and aims are those after Sullivan Pepe et al., 2001. MA: main aim. S1 S2 S3 S4: secondary aims 1 2 3 and 4. ✓ achieved, ± partly achieved, ⊙ to be done, NA not applicable.

			Phase 2					Phase 3					Phase 4					Phase 5		
			MA	SA1	SA2	SA3	SA4	MA	SA1	SA2	SA3	SA4	MA	SA1	SA2	SA3	SA4	MA	SA1	SA2
Core AD	CSF	Aβ42	✓	⊙	±	✓	±	✓	±	±	±	NA	⊙					⊙		
	CSF	tau, ph-tau	✓	⊙	±	✓	±	✓	⊙	±	±	NA								
	PET	¹¹ C-PIB, ¹⁸ F ligands	✓	✓	✓	✓	±	✓	⊙	⊙	⊙	NA	⊙	⊙	⊙	±	⊙			
	PET	¹⁸ F-FDG	✓	±	✓	✓	±	✓	±	±	±	NA	⊙							
	MR	3D T1-weighted	✓	±	✓	✓	±	✓	±	±	±	NA								
Others	SPECT	¹²³ I-ioflupane	✓	±	✓	✓	⊙	⊙	⊙	±	⊙	NA	⊙							
	SPECT	¹²³ I-MIBG	✓	±	⊙	✓	⊙	⊙	⊙	±	⊙	NA								
	Serum	Progranulin	✓	±	⊙	✓	±	✓	⊙	⊙	⊙	NA								